European stock markets ended the week without a clear direction, as investors digested a batch of economic data that met expectations and a series of regulatory updates that gave healthcare stocks a boost. The pan-European indexes finished mixed, with gains in pharma offset by caution elsewhere.
GDP matches forecasts, but hiring stalls
Eurostat, the European Union's statistics agency, reported that the euro area economy grew 0.4% in the third quarter compared with the previous three months, while the wider EU expanded 0.5%. Both figures matched the forecasts analysts had penciled in, according to a Bloomberg survey. On an annual basis, the euro area grew 1.3% and the EU grew 1.5%.
But the labor market told a less upbeat story. Employment was flat in both the euro area and the EU compared with the prior quarter, suggesting that businesses are holding off on hiring even as output expands. That combination—modest growth with no new jobs—can signal that productivity gains, rather than a broad-based recovery, are driving the numbers.
For everyday investors, the takeaway is that the European economy is growing, but not at a pace that would force central banks to change course. The European Central Bank has been gradually cutting interest rates as inflation cools, and these figures are unlikely to alter that trajectory. Slower hiring could even reinforce the case for further cuts, as policymakers watch for signs of weakness in the labor market.
Healthcare stocks get a lift from regulatory news
With the macro data offering few surprises, company-specific news took center stage. Danish drugmaker Novo Nordisk rose after it filed its once-daily oral sickle-cell treatment, etavopivat, with both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The filing follows phase 3 trial results showing the drug reduced painful 'vaso-occlusive crises' by 27% compared with placebo. These crises, caused by blocked blood vessels, are a hallmark of sickle-cell disease and a major source of hospitalizations.
Novo Nordisk said it does not expect regulatory decisions until 2027, meaning the drug is still years away from reaching the market. That timeline is crucial for investors. When a company files a drug for approval, the market's focus shifts from clinical efficacy to the probability of approval and the timing of future revenue. Because etavopivat's potential sales are so far off, they are heavily discounted in today's share price. Investors also apply a 'haircut' for the risk that regulators may reject the drug or restrict its use to a narrower patient group than the company hopes.
That explains why strong trial data can sometimes produce only a modest share-price move on the day. The bigger swings often come later, when the approval decision draws closer and the details of the label—what the drug is officially approved to treat—become clearer.
UK-based AstraZeneca also edged higher after the EMA's Committee for Medicinal Products for Human Use recommended approval of Baxfendy, its therapy for high blood pressure. A positive recommendation from this committee is a key step toward final approval in the European Union, though it is not the last word.
What it means for investors
For investors, the mixed market close reflects a broader uncertainty about the European economy. Growth is holding up, but the flat employment numbers raise questions about whether the recovery has legs. If companies are not hiring, consumer spending could eventually weaken, which would feed back into slower growth.
At the same time, the healthcare sector's resilience shows how company-specific catalysts can drive returns even when the macro picture is murky. Regulatory news, clinical trial results, and product approvals are events that investors can analyze and react to, regardless of what the GDP data says.
For those watching the European economy, the next key data points will be inflation readings and any signals from the European Central Bank about the pace of future rate cuts. The GDP figures released this week are unlikely to change the central bank's near-term plans, but a sustained stall in hiring could eventually prompt a more aggressive easing cycle.
As always, it's worth remembering that market moves on any given day are rarely driven by a single factor. The combination of in-line economic data and positive regulatory news for two major drugmakers created a mixed tape, with investors weighing the steady but unspectacular growth outlook against pockets of corporate optimism.
